作者
Lorraine C. Axford,Piyush K. Agarwal,Kelly H. Anderson,Laura Andrau,John Atherall,Stephanie Barker,James M. Bennett,Michael Blair,Ian Collins,Lloyd G. Czaplewski,David T. Davies,Carlie T. Gannon,Dushyant Kumar,Paul Lancett,Alastair Logan,Christopher J. Lunniss,Dale R. Mitchell,D.A. Offermann,James T. Palmer,Norman D. Palmer,Gary R.W. Pitt,Stéphanie Pommier,D J Price,B. Narasinga Rao,Rashmi Saxena,Tarun Shukla,Amit Kumar Singh,Mahipal Singh,P.R. Maulik,Christopher Steele,Neil R. Stokes,Helena Thomaides‐Brears,Edward M. Tyndall,David I. Watson,David J. Haydon
摘要
The discovery and optimisation of a new class of benzothiazole small molecules that inhibit bacterial DNA gyrase and topoisomerase IV are described. Antibacterial properties have been demonstrated by activity against DNA gyrase ATPase and potent activity against Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes and Haemophilus influenzae. Further refinements to the scaffold designed to enhance drug-likeness included analogues bearing an α-substituent to the carboxylic acid group, resulting in excellent solubility and favourable pharmacokinetic properties.